507 related articles for article (PubMed ID: 15798202)
1. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.
Rankin EB; Higgins DF; Walisser JA; Johnson RS; Bradfield CA; Haase VH
Mol Cell Biol; 2005 Apr; 25(8):3163-72. PubMed ID: 15798202
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
3. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.
Rankin EB; Tomaszewski JE; Haase VH
Cancer Res; 2006 Mar; 66(5):2576-83. PubMed ID: 16510575
[TBL] [Abstract][Full Text] [Related]
4. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
6. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
7. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
8. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Beppu K; Nakamura K; Linehan WM; Rapisarda A; Thiele CJ
Cancer Res; 2005 Jun; 65(11):4775-81. PubMed ID: 15930297
[TBL] [Abstract][Full Text] [Related]
9. Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma.
Choi JW; Park SC; Kang GH; Liu JO; Youn HD
Cancer Res; 2004 Jan; 64(1):35-9. PubMed ID: 14729605
[TBL] [Abstract][Full Text] [Related]
10. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
11. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.
Haase VH; Glickman JN; Socolovsky M; Jaenisch R
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1583-8. PubMed ID: 11171994
[TBL] [Abstract][Full Text] [Related]
12. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
13. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.
Pastore Y; Jedlickova K; Guan Y; Liu E; Fahner J; Hasle H; Prchal JF; Prchal JT
Am J Hum Genet; 2003 Aug; 73(2):412-9. PubMed ID: 12844285
[TBL] [Abstract][Full Text] [Related]
14. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the tumor suppressor gene von Hippel-Lindau (VHL) in granulocytes contributes to development of liver hemangiomas in a mouse model.
Bader HL; Hsu T
BMC Cancer; 2016 Oct; 16(1):797. PubMed ID: 27733136
[TBL] [Abstract][Full Text] [Related]
16. The von Hippel-Lindau tumor suppressor protein.
Ivan M; Kaelin WG
Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
[TBL] [Abstract][Full Text] [Related]
17. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
18. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice.
Rankin EB; Rha J; Unger TL; Wu CH; Shutt HP; Johnson RS; Simon MC; Keith B; Haase VH
Oncogene; 2008 Sep; 27(40):5354-8. PubMed ID: 18490920
[TBL] [Abstract][Full Text] [Related]
20. EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate.
Pascal LE; Ai J; Rigatti LH; Lipton AK; Xiao W; Gnarra JR; Wang Z
Angiogenesis; 2011 Sep; 14(3):331-43. PubMed ID: 21638067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
